Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib and Atezolizumab in Advanced Urothelial Cancer
NCT04045613Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of derazantinib in urothelial carcinoma (UC), sponsored by Basilea Pharmaceutica. Started Aug 2019; status: completed.
02
Drugs
derazantinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04045613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045613.